Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: A review of Phase III clinical data

Expert Review of Endocrinology and Metabolism

Volumn 8, Issue 2, 2013, Pages 105-121

  Raccah, Denis ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

basal insulin; glucagon like peptide 1; HbA1c; insulin; lixisenatide; postprandial glucose; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA;

ADD ON THERAPY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED DRUG RELEASE; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 84874626121     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.12.82     Document Type: Article

References (66)

1. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (7258), 405-412 (2000).
2. Khaw KT, Wareham N. Glycated hemoglobin as a marker of cardiovascular risk. Curr. Opin. Lipidol. 17 (6), 637-643 (2006).
3. Selvin E, Ning Y, Steffes MW et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 60 (1), 298-305 (2011).
4. Yu PC, Bosnyak Z, Ceriello A. The importance of glycated haemoglobin (HbA (1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with Type 2 diabetes. Diabetes Res. Clin. Pract. 89 (1), 1-9 (2010).
5. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 33 (Suppl. 1), S11-S61 (2010).
6. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in Type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55 (6), 1577-1596 (2012).
7. International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet. Med. 23 (6), 579-593 (2006).
8. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28 (2), 103-117 (1995).
9. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352 (9131), 837-853 (1998).
10. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 26 (3), 881-885 (2003).
11. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30 (2), 263-269 (2007).
12. Ceriello A, Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet. Med. 25 (10), 1151-1156 (2008).
13. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in Type 2 diabetes. Diabetes Care 34 (12), 2508-2514 (2011).
14. Leiter LA, Ceriello A, Davidson JA et al.; International Prandial Glucose Regulation Study Group. Postprandial glucose regulation: new data and new implications. Clin. Ther. 27 (Suppl. B), S42-S56 (2005).
15. Woerle HJ, Neumann C, Zschau S et al. Impact of fasting and postprandial glycemia on overall glycemic control in Type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res. Clin. Pract. 77 (2), 280-285 (2007).
16. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in Type 2 diabetes mellitus is not enough -what next? Diabetes Metab. Res. Rev. 23 (4), 257-264 (2007).
17. Edelman SV. Optimizing diabetes treatment using an amylin analogue. Diabetes Educ. 34 (Suppl. 1), 4S-10S (2008).
18. Edelman S, Maier H, Wilhelm K. Pramlintide in the treatment of diabetes mellitus. BioDrugs 22 (6), 375-386 (2008).
19. Holst JJ. The physiology of glucagon-like peptide 1. Physiol. Rev. 87 (4), 1409-1439 (2007).
20. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in Type 2 diabetic patients and in healthy subjects. Diabetes 44 (9), 1126-1131 (1995).
21. Ruiz-Grande C, Pintado J, Alarcón C, Castilla C, Valverde I, López-Novoa JM. Renal catabolism of human glucagon-like peptides 1 and 2. Can. J. Physiol. Pharmacol. 68 (12), 1568-1573 (1990).
22. Drucker DJ. Enhancing incretin action for the treatment of Type 2 diabetes. Diabetes Care 26 (10), 2929-2940 (2003).
23. Christensen M, Knop FK, Vilsbøll T, Holst JJ. Lixisenatide for Type 2 diabetes mellitus. Expert Opin. Investig. Drugs 20 (4), 549-557 (2011).
24. Hansen KB, Vilsbøll T, Knop FK. Incretin mimetics: a novel therapeutic option for patients with Type 2 diabetes - a review. Diabetes. Metab. Syndr. Obes. 3, 155-163 (2010).
25. Morales J. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad. Med. 123 (6), 189-201 (2011).
26. Mathieu C. Can we reduce hypoglycaemia with insulin detemir? Int. J. Obes. Relat. Metab. Disord. 28 (Suppl. 2), S35-S40 (2004).
27. Levetan C. Oral antidiabetic agents in Type 2 diabetes. Curr. Med. Res. Opin. 23 (4), 945-952 (2007).
28. McFarlane SI. Insulin therapy and Type 2 diabetes: management of weight gain. J. Clin. Hypertens. (Greenwich) 11 (10), 601-607 (2009).
29. Abrahamson MJ. Basal insulins: pharmacological properties and patient perspectives. Prim. Care Diabetes 4 (Suppl. 1), S19-S23 (2010).
30. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet 368 (9548), 1696-1705 (2006).
31. Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat Type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur. J. Endocrinol. 158 (6), 773-784 (2008).
32. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) - preclinical and clinical results. Best Pract. Res. Clin. Endocrinol. Metab. 23 (4), 463-477 (2009).
33. Christensen M, Knop FK. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr. Diab. Rep. 10 (2), 124-132 (2010).
34. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly glucagon-like peptide-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes. Obes. Metab. 13 (5), 394-407 (2011).
35. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of Type 2 diabetes. Regul. Pept. 164 (2-3), 58-64 (2010).
36. Thorkildsen C, Neve S, Larsen BD, Meier E, Petersen JS. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J. Pharmacol. Exp. Ther. 307 (2), 490-496 (2003).
37. Becker RH, Ruus P, Liu Y-H, Kapitza C. Restoration of insulin release with lixisenatide in patients with Type 2 diabetes. Diabetologia 53 (Suppl. 1), S339 (2010).
38. Haschke G, Haag-Diergarten S, Werner U, Kramer W, Herling AW. The GLP-1 receptor agonist AVE0010 preserves β cell function and insulin secretion after a 6 week treatment in male obese Zucker diabetic fatty rats - an isolated perfused pancreas study. Diabetologia 49, 400-401 (2006).
39. Hansen M, Hare KJ, Holst JJ, Knop FK. Inhibition of glucagon secretion by GLP-1 agonists and DPP4 inhibitors. J. Clin. Metabol. Diabet. 2, 7-13 (2011).
40. Kapitza C, Coester HV, Poitiers F, Heumann G, Ruus G, Méry AH. Pharmacodynamic characteristics of lixisenatide once daily vs liraglutide once daily in patients with T2DM inadequately controlled with metformin. Diabetes Obes. Metab. doi:10.1111/dom.12076 (2013) (Epub ahead of print).
41. Chia CW, Egan JM. Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes. Metab. Syndr. Obes. 2, 37 (2009).
42. Barnett AH. Lixisenatide: evidence for its potential use in the treatment of Type 2 diabetes. Core Evid. 6, 67-79 (2011).
43. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 (8), 741-744 (1993).
44. Distiller LA, Ruus P; on behalf of the Act6011 Study Group. Pharmacokinetics and pharmacodynamics of a new GLP-1 agonist AVE0010 in Type 2 diabetes patients. Diabetes 57 (Suppl. 1), A154-A155. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6-10 June 2008 (Abstract 520-P).
45. Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators. Dosedependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet. Med. 27 (9), 1024-1032 (2010).
46. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebocontrolled trial in patients with Type 2 diabetes (GetGoal-Mono). Diabetes Care 35 (6), 1225-1231 (2012).
47. Bolli G, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Hanefeld M. Efficacy and safety of lixisenatide once-daily versus placebo in patients with Type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1). Diabetologia 54 (Suppl. 1), S1-S542. Presented at: 47th European Association for the Study of Diabetes Annual Meeting. Lisbon, Portugal, 12-16 September 2011 (Abstract 784).
48. Aronson R, Ahrén B, Dimas AL, Miossec P, Saubadu S. Efficacy and safety of once-daily lixisenatide morning or evening injections vs placebo (GetGoal-M). Presented at: IDF World Diabetes Congress. Dubai, UAE, 4-8 December 2011 (Abstract 0-0591).
49. Ratner RE, Hanefeld M, Shamanna P et al. Post-meal pharmacodynamic profile of lixisenatide once daily vs placebo in T2DM insufficiently controlled on SU±metformin (GetGoal-S). Presented at: IDF World Diabetes Congress. Dubai, UAE, 4-8 December 2011.
50. Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in patients with Type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes 61 (Suppl. 1), A212-A344. Presented at: 72nd Scientific Sessions of the American Diabetes Association. Philadelphia, PA, USA, 8-12 June 2012 (Abstract 1010-P).
51. Rosenstock J, Raccah D, Korányi L et al. Efficacy and safety of lixisenatide once daily vs exenatide twice daily in Type 2 DM inadequately controlled on metformin (GetGoal-X). Presented at: 71st Scientific Sessions of the American Diabetes Association. San Diego, CA, USA, 24-28 June 2011.
52. Riddle M, Home P, Marre M, Niemoeller E, Ping L, Rosenstock J. Efficacy and safety of once-daily lixisenatide in Type 2 diabetes insufficiently controlled with basal insulin ± metformin: GetGoal-L Study. Diabetes 61 (Suppl. 1), A212-A344. Presented at: 72nd Scientific Sessions of the American Diabetes Association. Philadelphia, PA, USA, 8-12 June 2012 (Abstract 983-P).
53. Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with Type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-LAsia). Diabetes. Obes. Metab. 14 (10), 910-917 (2012).
54. Rosenstock J, Forst T, Aronson R et al. Efficacy and safety of once-daily lixisenatide added on to titrated glargine plus oral agents in Type 2 diabetes: GetGoal-Duo 1 Study. Diabetes 61 (Suppl. 1), A18. Presented at: 72nd Scientific Sessions of the American Diabetes Association. Philadelphia, PA, USA, 8-12 June 2012 (Abstract 62-OR).
55. Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in basal insulin-treated patients with Type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. 154 (2), 103-112 (2011).
56. Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with Type 2 diabetes: a randomized, double-blind, placebocontrolled, parallel-group study. Clin. Ther. 30 (8), 1448-1460 (2008).
57. Garber A, Henry R, Ratner R et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet 373 (9662), 473-481 (2009).
58. Raccah D, Miossec P, Esposito V, Niemoeller E, Cho M, Gerich J. Efficacy and safety of lixisenatide in elderly (≥65 yr) and very elderly (≥75 yr) patients with Type 2 diabetes: an analysis from the GetGoal Phase 3 program. Diabetes 61 (Suppl. 1), A248 (2012) (Abstract 972-P).
59. de Heer J, Holst JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 56 (2), 438-443 (2007).
60. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care 26 (11), 3080-3086 (2003).
61. Monnier L. Comment on: Riddle et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in Type 2 diabetes. Diabetes Care 35 (1), e2; author reply e3 (2012).
62. Lorenz M, Pfeiffer C, Steinsträßer A, Ruus P. Effects of lixisenatide once daily on gastric emptying and relationship to postprandial glycemia in Type 2 diabetes mellitus. Diabetes Care 61 (Suppl. 1), A212-A344 (2012).
63. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60 (5), 1561-1565 (2011).
64. Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes. Obes. Metab. 13 (9), 814-822 (2011).
65. International Diabetes Federation. Guideline for Management of Postmeal Glucose in Diabetes (2011). www.idf.org/sites/default/files/ postmeal%20glucose%20guidelines.pdf (Accessed 7 June 2012)
66. ClinicalTrials.gov identifier: NCT01147250. Evaluation of cardiovascular outcomes in patients with Type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (Lixisenatide) (ELIXA). www.ClinicalTrials.gov